OR WAIT null SECS
January 11, 2023
Chiesi will acquire Amryt Pharma, a commercial-stage biopharmaceutical company, in a deal worth up to $1.47 billion.
Ipsen’s $952 million acquisition of Albireo is designed to bolster the company's rare disease portfolio.
Sartorius and RoosterBio will work together to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies.
January 10, 2023
The collaboration will see Moderna and CytomX work together to develop mRNA-based conditionally activated therapeutics.
January 04, 2023
Agilent’s acquisition of Avida grants them access to high-performance enrichment workflows that enable NGS approaches for studying cancer.
Merck, known as MSD outside of the United States and Canada, will pay Kelun-Biotech up to $9l3 billion for seven early-stage oncology treatments.
January 02, 2023
The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.
December 19, 2022
GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.
AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
December 14, 2022
Under the collaboration between Vertex and Entrada, the companies will work on discovering and developing intracellular endosomal escape vehicle therapeutics for myotonic dystrophy type 1.